FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894029576> ?p ?o ?g. }

• W2894029576 endingPage "74s" @default.
• W2894029576 startingPage "74s" @default.
• W2894029576 abstract "Background: State health insurance authorities in Greece do not reimburse genetic testing for cancer predisposition. The Hellenic Society of Medical Oncology has launched and carries out a national program covering genetic testing for BRCA1/2 mutations detection, with the financial support of pharmaceutical industry. Aim: This analysis evaluates how, during this program, access to genetic testing transformed the oncologists' therapeutic approach toward their ovarian cancer patients and how the results impacted treatment decisions concerning PARP inhibitors. Adoption of testing by healthy relatives and timing of testing in the disease continuum were also evaluated. Methods: Adult patients with high-grade epithelial ovarian carcinoma, irrespectively of family history or age at diagnosis were eligible for this program. Genetic counseling was recommended before testing, and both were offered at no financial cost. First degree family members of pathogenic mutation carriers were also offered free counseling and testing. Results: From March 2015 through January 2018, 708 patients were enrolled and tested. One hundred and forty seven (20.7%) mutation carriers were identified, 102 (14.4%) in BRCA1 and 45 (6.3%) in BRCA2 gene. Testing was more often pursued at initial diagnosis (61%) than at recurrence (39%), as recorded for 409 patients with available relevant information. During the 1st year of the program, average monthly tests performed were 25.1, while during the 3rd year this number increased to 34.3 tests per month. Among patients who tested positive for deleterious BRCA1/2 mutations, relapse was reported in 58 patients, 94.8% of which (n= 55) received treatment with the PARP inhibitor olaparib as per its indication. Family members of 21 patients (14.3%), out of the 147 who tested positive, received genetic counseling and testing for the mutation identified in the context of the program. Conclusion: Free access to genetic testing for BRCA1/2 for ovarian cancer patients and genetic consultation facilitates testing uptake, affects common clinical practice & has major impact on patients and their families. Still, diffusion of genetic information and broader testing of family members require further efforts by the oncological community." @default.
• W2894029576 created "2018-10-05" @default.
• W2894029576 creator A5001577925 @default.
• W2894029576 creator A5002334565 @default.
• W2894029576 creator A5005232768 @default.
• W2894029576 creator A5005525687 @default.
• W2894029576 creator A5005647074 @default.
• W2894029576 creator A5008322636 @default.
• W2894029576 creator A5010518871 @default.
• W2894029576 creator A5011100768 @default.
• W2894029576 creator A5015208683 @default.
• W2894029576 creator A5015401016 @default.
• W2894029576 creator A5015687679 @default.
• W2894029576 creator A5017024960 @default.
• W2894029576 creator A5019893325 @default.
• W2894029576 creator A5021778173 @default.
• W2894029576 creator A5022772346 @default.
• W2894029576 creator A5024483658 @default.
• W2894029576 creator A5029860089 @default.
• W2894029576 creator A5030559663 @default.
• W2894029576 creator A5032441870 @default.
• W2894029576 creator A5032663338 @default.
• W2894029576 creator A5034130579 @default.
• W2894029576 creator A5035832029 @default.
• W2894029576 creator A5038658430 @default.
• W2894029576 creator A5040684248 @default.
• W2894029576 creator A5042177139 @default.
• W2894029576 creator A5043943818 @default.
• W2894029576 creator A5044888054 @default.
• W2894029576 creator A5044908188 @default.
• W2894029576 creator A5047544017 @default.
• W2894029576 creator A5047839939 @default.
• W2894029576 creator A5048322584 @default.
• W2894029576 creator A5051159397 @default.
• W2894029576 creator A5054986572 @default.
• W2894029576 creator A5059277687 @default.
• W2894029576 creator A5059774082 @default.
• W2894029576 creator A5061193434 @default.
• W2894029576 creator A5071300210 @default.
• W2894029576 creator A5072900712 @default.
• W2894029576 creator A5075922494 @default.
• W2894029576 creator A5076032623 @default.
• W2894029576 creator A5081659797 @default.
• W2894029576 creator A5085021572 @default.
• W2894029576 creator A5086201176 @default.
• W2894029576 creator A5086594420 @default.
• W2894029576 creator A5087044163 @default.
• W2894029576 creator A5087479328 @default.
• W2894029576 creator A5087582732 @default.
• W2894029576 creator A5087834972 @default.
• W2894029576 creator A5089872275 @default.
• W2894029576 creator A5090741343 @default.
• W2894029576 date "2018-10-01" @default.
• W2894029576 modified "2023-10-17" @default.
• W2894029576 title "Access to Genetic Testing Impacts Oncologists´ Decisions on Ovarian Cancer Personalized Treatment: Lessons Learned From a National Program in Greece" @default.
• W2894029576 doi "https://doi.org/10.1200/jgo.18.55800" @default.
• W2894029576 hasPublicationYear "2018" @default.
• W2894029576 type Work @default.
• W2894029576 sameAs 2894029576 @default.
• W2894029576 citedByCount "0" @default.
• W2894029576 crossrefType "journal-article" @default.
• W2894029576 hasAuthorship W2894029576A5001577925 @default.
• W2894029576 hasAuthorship W2894029576A5002334565 @default.
• W2894029576 hasAuthorship W2894029576A5005232768 @default.
• W2894029576 hasAuthorship W2894029576A5005525687 @default.
• W2894029576 hasAuthorship W2894029576A5005647074 @default.
• W2894029576 hasAuthorship W2894029576A5008322636 @default.
• W2894029576 hasAuthorship W2894029576A5010518871 @default.
• W2894029576 hasAuthorship W2894029576A5011100768 @default.
• W2894029576 hasAuthorship W2894029576A5015208683 @default.
• W2894029576 hasAuthorship W2894029576A5015401016 @default.
• W2894029576 hasAuthorship W2894029576A5015687679 @default.
• W2894029576 hasAuthorship W2894029576A5017024960 @default.
• W2894029576 hasAuthorship W2894029576A5019893325 @default.
• W2894029576 hasAuthorship W2894029576A5021778173 @default.
• W2894029576 hasAuthorship W2894029576A5022772346 @default.
• W2894029576 hasAuthorship W2894029576A5024483658 @default.
• W2894029576 hasAuthorship W2894029576A5029860089 @default.
• W2894029576 hasAuthorship W2894029576A5030559663 @default.
• W2894029576 hasAuthorship W2894029576A5032441870 @default.
• W2894029576 hasAuthorship W2894029576A5032663338 @default.
• W2894029576 hasAuthorship W2894029576A5034130579 @default.
• W2894029576 hasAuthorship W2894029576A5035832029 @default.
• W2894029576 hasAuthorship W2894029576A5038658430 @default.
• W2894029576 hasAuthorship W2894029576A5040684248 @default.
• W2894029576 hasAuthorship W2894029576A5042177139 @default.
• W2894029576 hasAuthorship W2894029576A5043943818 @default.
• W2894029576 hasAuthorship W2894029576A5044888054 @default.
• W2894029576 hasAuthorship W2894029576A5044908188 @default.
• W2894029576 hasAuthorship W2894029576A5047544017 @default.
• W2894029576 hasAuthorship W2894029576A5047839939 @default.
• W2894029576 hasAuthorship W2894029576A5048322584 @default.
• W2894029576 hasAuthorship W2894029576A5051159397 @default.
• W2894029576 hasAuthorship W2894029576A5054986572 @default.
• W2894029576 hasAuthorship W2894029576A5059277687 @default.
• W2894029576 hasAuthorship W2894029576A5059774082 @default.
• W2894029576 hasAuthorship W2894029576A5061193434 @default.
• W2894029576 hasAuthorship W2894029576A5071300210 @default.

• next